Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Rekvina Labs
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel

Rekvina Labs

WEBSITE BSE:526075 NSE: REKVINA LAB. Inc. Year: 1988 Industry: Trading My Bucket: Add Stock

₹40 0 | 0%

Last updated: 11:16

Consolidated Standalone

Last updated: 11:16

My Notes

No Notes Added Yet

Rekvina Labs Overview

Rekvina Laboratories Ltd is an Indian company engaged in the pharmaceutical and healthcare sector, focusing on the manufacturing, formulation, and marketing of medicines and healthcare products. The company caters to domestic and international markets, emphasizing product quality, regulatory compliance, and research-driven development. Rekvina Laboratories Ltd aims to provide effective healthcare solutions while maintaining operational efficiency and expanding its presence in the competitive pharmaceutical industry.

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Rekvina Labs Key Financials

Market Cap ₹24 Cr.

Stock P/E -175.7

P/B -45.8

Current Price ₹40

Book Value ₹ -0.9

Face Value 5

52W High ₹46.7

Dividend Yield 0%

52W Low ₹ 6.8

Edit Ratio

Rekvina Labs Share Price

₹ | |

Volume
Price

Rekvina Labs Quarterly Price

Quarterly Monthly
Show Value Show %

Rekvina Labs Peer Comparison

Rekvina Labs Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 0 0 0 0 0 0 0 0 0 0
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 0 0 0 0 0 0
Total Expenditure 0 0 0 0 0 0 0 0 0 0
Operating Profit -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Provision for Tax 0 0 0 0 0 0 0 0 0 0
Profit After Tax -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Adjusted Earnings Per Share -0 -0 -0 -0 -0.1 -0 -0.1 -0.1 -0.1 -0.2

Rekvina Labs Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 0 0 0 0 0 0 0 0 0 0 0 0
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Total Income 0 0 0 0 0 0 0 0 0 0 0 0
Total Expenditure 0 0 0 0 0 0 0 0 0 0 0 0
Operating Profit 0 -0 -0 -0 -0 0 -0 -0 -0 -0 -0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 -0 -0 -0 -0 0 -0 -0 -0 -0 -0 0
Provision for Tax 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Tax 0 -0 -0 -0 -0 0 -0 -0 -0 -0 -0 0
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 -0 -0 -0 -0 0 -0 -0 -0 -0 -0 0
Adjusted Earnings Per Share 0 -0.1 -0 -0.1 -0.4 0 -0.1 -0.1 -0 -0 -0.2 -0.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 0% 0% 0% 0%
Operating Profit CAGR 0% 0% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 788% 107% 59% 23%
ROE Average 0% -0% -40% -29%
ROCE Average 0% -0% -35% -21%

Rekvina Labs Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 1 1 0 0 0 0 0 0 0 -0 -0
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0 0
Total Current Liabilities 0 0 0 0 0 0 0 0 0 0 0
Total Liabilities 1 1 1 1 0 0 0 0 0 0 0
Fixed Assets 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0 0 0 0 0 0 0
Total Current Assets 0 0 1 1 0 0 0 0 0 0 0
Total Assets 1 1 1 1 0 0 0 0 0 0 0

Rekvina Labs Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0 0 0
Cash Flow from Operating Activities -0 -0 0 -0 0 -0 -0 -0 0 -0 -0
Cash Flow from Investing Activities 0 0 -0 0 0 0 0 0 0 0 0
Cash Flow from Financing Activities 0 -0 0 0 -0 -0 -0 -0 -0 0 0
Net Cash Inflow / Outflow 0 0 0 0 -0 -0 -0 -0 0 -0 0
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 0 0 0

Rekvina Labs Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.01 -0.09 -0.03 -0.13 -0.42 0 -0.11 -0.13 -0 -0.03 -0.23
CEPS(Rs) 0.01 -0.09 -0.03 -0.13 -0.42 0 -0.11 -0.13 -0 -0.03 -0.23
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0.93 0.84 0.81 0.67 0.26 0.26 0.15 0.02 0.02 -0.32 -0.55
Core EBITDA Margin(%) 15.4 -89.93 0 0 0 0 0 0 0 0 0
EBIT Margin(%) 15.4 -89.81 0 0 0 0 0 0 0 0 0
Pre Tax Margin(%) 14.96 -89.99 0 0 0 0 0 0 0 0 0
PAT Margin (%) 12.19 -89.99 0 0 0 0 0 0 0 0 0
Cash Profit Margin (%) 12.19 -89.99 0 0 0 0 0 0 0 0 0
ROA(%) 0.56 -8.69 -2.69 -10.03 -45.95 0.84 -24.61 -36.27 -0.14 -15.53 -652.86
ROE(%) 0.64 -10.61 -3.89 -17.91 -89.61 1.54 -51.4 -147.84 -0.33 0 0
ROCE(%) 0.81 -10.39 -3.28 -12.59 -30.45 1.73 -51.32 -125.91 -0.1 0 0
Receivable days 2634.82 1533.52 0 0 0 0 0 0 0 0 0
Inventory Days 0 0 0 0 0 0 0 0 0 0 0
Payable days 0 0 0 0 0 0 0 0 0 0 0
PER(x) 1971.21 0 0 0 0 1042.5 0 0 0 0 0
Price/Book(x) 13.97 6.34 6.59 0 19.69 16.01 25.79 0 0 0 0
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 239.27 50.62 0 0 0 0 0 0 0 0 0
EV/Core EBITDA(x) 1553.43 -56.36 -168.53 -38.51 -25.88 926.92 -37.3 -44.86 0 -185.61 -23.6
Net Sales Growth(%) -57.78 91.59 -100 0 0 0 0 0 0 0 0
EBIT Growth(%) -81.89 -1217.13 65.97 -315.47 -46.24 102.31 -2474.07 -4.81 99.62 -5366.67 -735.98
PAT Growth(%) -82.16 -1514.39 65.91 -313.95 -214.66 100.96 -2775 -22.87 99.12 -2242.86 -735.98
EPS Growth(%) -82.26 -1521.21 65.88 -313.75 -214.65 100.96 -2762.5 -22.91 99.08 -2166.67 -736.03
Debt/Equity(x) 0.02 0.02 0.35 0.51 0 0 0 0 0 -0.2 -0.74
Current Ratio(x) 4.34 2.97 1.83 1.44 0.42 0.37 0.06 0 0.05 0.05 0.09
Quick Ratio(x) 4.34 2.97 1.83 1.44 0.42 0.37 0.06 0 0.05 0.05 0.09
Interest Cover(x) 34.6 -513.53 -271.88 0 -291.75 9 -641 -19.85 -0.75 0 0
Total Debt/Mcap(x) 0 0 0.05 0 0 0 0 0 0 0 0

Rekvina Labs Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 41.3 45.09 41.3 41.3 41.3 41.3 41.3 41.3 41.3 41.3
FII 0 0 0 0 0 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 58.7 54.91 58.7 58.7 58.7 58.7 58.7 58.7 58.7 58.7
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Rekvina Labs News

Rekvina Labs Pros & Cons

Pros

  • Stock is trading at -45.8 times its book value
  • Company is almost debt free.

Cons

  • Promoter holding is low: 41.3%.
  • Company has a low return on equity of -0% over the last 3 years.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!